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MicroarrayMicroRNAs (miRNA) can regulate cancer cell proliferation and metastasis. Here, we show that
miR-338-3p is down-regulated in metastatic tumor tissues compared to primary tumors, and that
that miR-338-3p can inhibit cell proliferation by inducing cell cycle arrest, as well as restrain cell
migration and invasion. PREX2a is conﬁrmed as a direct target of miR-338-3p. Knockdown of
PREX2a inhibits cell proliferation, migration and invasion through the PTEN/Akt pathway.
miR-338-3p-dependent inhibition of proliferation and invasion can be rescued by PREXa. Overall,
this study demonstrates that miR-338-3p affects the PTEN/Akt pathway by down-regulating PREX2a.
This newly identiﬁed function of miR-338-3p provides novel insights into neuroblastoma and may
foster therapeutic applications.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction into focus, which could be potential serving as new therapeuticNeuroblastoma (NB), one of the most common forms of cancer
in young children, originates from precursor cells of the
sympathetic nervous system, accounting for 7% of childhood
malignancies and 15% of pediatric cancer-related deaths [1]. It is
a heterogenous disease, ranging from spontaneous regression
without treatment to rapid disease progression and mortality.
Despite advances in treatment and disease management, the over-
all 5-year survival rates remain poor in high-risk disease (25–40%).
Seventy-three percent of patients with NB have already developed
malignant lesions outside the primary tumor at the time of diagno-
sis [2]. Although a number of genetic and molecular lesions have
been correlated with NB tumorigenesis, the molecular basis of this
tumor is still far away from being completely understood. Elucidat-
ing the mechanism will potentially contribute to a greater under-
standing of response to therapy, leading to the identiﬁcation of
suitable therapeutic agents.
To clarify the mechanism, a recently discovered class of genes
transcribing small non-coding RNAs, namely microRNAs, comestrategies for cancers. MicroRNAs are 20–22 nucleotide molecules
which can regulate gene expression through RNA interference
effecter complex (RISC) mediated mRNA degradation or transla-
tional suppression via complimentary pairing predominantly to
the 30-untranslated region (30-UTR) of their targeted messenger
RNAs [3]. Recently, an increasing number of studies have demon-
strated the misexpression patterns of miRNAs in many human can-
cers participating in critical pathways linked to proliferation, cell
cycle progression and metastasis [4]. Several miRNAs have been
linked to MYCN, a risk factor of NB. For example, Swarbrick, et al.
found miR-380-3p increased tumor growth by repressing p53
and was associated with poor outcome in MYCN-ampliﬁed neuro-
blastoma [5]. Recently, researchers identiﬁed that over-expression
of miR-497 resulted in signiﬁcantly cell cycle arrest at G0/G1 and
G2/M phase in MYCN-ampliﬁed neuroblastoma Kelly cells. Further
analysis revealed miR-497 functioned through targeting 3UTR of
WEE1, a tyrosine kinase regulator of the cell cycle [6]. Furthermore,
cytoﬂuorimetric analysis conﬁrmed that an accumulation of a
G0/G1 phase population was observed in miR-214 down-regulated
in neuroblastoma SK-N-SH cells [7]. A study conducted by Zhang,
et al. demonstrated that miR-9 inhibited invasion and angiogenesis
in NB cells through targeting matrix metalloproteinase (MMP)-14
[8].
In our previous study, we showed a widespread alteration of 54
miRNAs in metastatic NB compared with primary NB, Among
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metastasis, because it was signiﬁcantly down-regulated in meta-
static NB compared to primary NB in animal models [2]. PREX2a
is a guanine nucleotide exchange factor (GEF) for the RAC guano-
sine triphosphatase (GTPase) [9]. The PREX2a gene is located on
chromosome 8q13, a region linked to frequent ampliﬁcation and
aggressive cancer phenotypes in breast, prostate, and colorectal
cancers [10]. In this report, we identify the important molecular
mechanism by which miR-338-3p exerts its negative effects on
neuroblastoma cell proliferation, migration and invasion in human
neuroblastoma cells, which involves the direct targeting the 30UTR
of PREX2a mRNA and affects the PTEN/Akt pathway.
2. Materials and methods
2.1. Human tissue samples
Eighteen paired neuroblastoma tissue sections from patients
with metastasis and primary tissues were obtained from the
Tumor Bank Facility of the Afﬁliated Hospital of Medical College,
Qingdao University, China. Detailed pathologic and clinical data
were collected for all samples including Edmondson tumor grade,
invasion and metastasis. The diagnoses of these samples were ver-
iﬁed by pathologists. The collection of human tissue samples was
approved and supervised by the Ethics Committee of Qingdao
University.
2.2. Cell culture and transfection
For the culture of cell lines used in this study, the human SH-
SY5Y neuroblastoma cells were cultivated in DMEM containing
10% fetal bovine serum plus 2 mM L-Glutamine. The GI-Li-N cell
was grown in 1640 medium supplemented with 10% fetal bovine
serum and 2 mM L-Glutamine. All cells were splitted before conﬂu-
ence and incubated at 37 C in a humidiﬁed incubator with 5% CO2.
MiR-338-3p mimics and miR-338-3p ASO were purchased from
Shanghai GenePharma (Shanghai, China). Transfections of miRNA
mimics and ASO were carried out using Lipofectamine-2000 (Invit-
rogen, Carlsbad, CA) according to the manufacturer’s instructions.
2.3. RNA preparation and quantitative PCR
RNA was extracted from cells or tissue samples using the mir-
Vana miRNA Isolation Kit (Ambion, USA) according to the manufac-
turer’s instructions. Small RNA fraction (smaller than 200 nt) were
separated and puriﬁed according to this procedure. cDNA was ob-
tained using M-MLV (Promega, USA) and 1 lg of obtained RNA. The
relative level of miR-338-3p was detected by stem-loop RT-PCR
with following conditions: denaturing the DNA at 94 C for
4 min, followed by 40 cycles of ampliﬁcation: 94 C for 60 s, 58 C
for 60 s, 72 C for 60 s for data collection. U6 snRNA was used as
an endogenous control. Quantitative PCR was performed on an
ABI 7500 thermocycler (Applied Biosystems) using SYBR Premix
Ex TaqTM (Perfect Real Time) Kits (TaKaRa, Japan) according to
the manufacturer’s instructions. The primers used are listed in
Table 2.
2.4. Microarray analysis
miRNA microarray chips were conducted as previously de-
scribed [11]. Brieﬂy, 50 lg total RNA was puriﬁed and labeled with
ﬂuorescein, and hybridization was carried out on miRNA micro-
array chip (CapitalBio Corp., Beijing, China) containing 508 probes
in triplicate, corresponding to predicted miR-338-3p targets. Final-
ly, hybridization signals were detected and scanner images were
quantiﬁed.2.5. Detection of cell proliferation capacity
To determine the cell proliferation capacity, cells were
examined with cell growth curve and colony formation assay. Cells
were seeded in triplicate in 24-well plates with 1  104 SH-SY5Y
and GI-Li-N cells per well and were counted over an 6-day period
since the second day. Cells were harvested by trypsinization and
counted for four times per well. The growth curves were drawn
for 6 days according to the mean values of the three wells. The
number of viable cell colonies were determined after 14 days of
inoculation 100 SH-SY5Y or GI-Li-N cells per well in 12-well plates
during colony formation assay. Colony formation ratio was calcu-
lated with the following equation: colony formation ratio
(%) = (number of colonies/number of seeded cells)  100.
2.6. Cell invasion and wound healing assays
A total of 5  104 SH-SY5Y and 1  105 GI-Li-N cells (in 0.2 ml
RPMI 1640 with 5% FBS) were seeded into the upper part of a
Transwell chamber (Corning, USA), which was pre-coated with
1 mg/ml Matrigel (Growth Factor Reduced BD MatrigelTM Matrix)
for 2 h. In the lower part of the chamber, 0.6 ml RPMI 1640 with
20% FBS was added. After incubating for 30 h, chambers were
disassembled and the membranes were stained with 2% crystal
violet for 10 min and placed on a glass slide. Then cells invasing
across the membrane were counted in 5 random visual ﬁelds un-
der a light microscope. All assays were performed in triplicate
and independently performed three times. For the wound healing
assay, 5  104 SH-SY5Y and 1  105 GI-Li-N cells were seeded into
24-well plates and cultured until conﬂuent. A P200 pipette tip
was used to make a straight line simulation ‘‘wound’’. Then cells
were washed several times with appropriate culture medium to
remove cell debris. The extent of wound closure was monitored
at 24 h.
2.7. Fluorescent reporter assays
The human PREX2a 30UTR harboring three miR-338-3p poten-
tial target-binding sequences was synthesized by GenPharm
(Shanghai, China). Luciferase constructs were made by ligating
the synthesized 30UTR as well as the seed-sequence mutated ver-
sion after the luc ORF in the pMIR-REPORT luciferase vector (Ambi-
on). For the ﬂuorescent reporter assay, cells were seeded in a
48-well plate the day before transfection. The cells were co-trans-
fected with miR-338-3p mimics or ASO as well as the controls and
PREX2a-3UTR or PREX2a-3UTRmut. The cells were lyzed 48 h later
and the intensity of luciferase was detected.
2.8. Western blotting
Western blotting was performed to determine protein
expression of PREX2a and Akt. Total protein from cells was
extracted by Trizol reagent (Invitrogen, USA) according to the
manufacturer’s instructions and cells were lyzed by RIPA buffer.
The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
regarded as the endogenous normalizer. The polyclonal rabbit
anti-human PREX2a, GAPDH (Saierbio, China) and Phospho-Akt
(Thr308, Ser473), Akt (cell signaling technology, New England
Biolabs) were used.
2.9. Knockdown of PREX2a by siRNA
The siRNA targeting PREX2a (region 153–177, GGAGTTCCTGGT
GTCGGCATTCTTA) was designed and synthesized by GenPharm
(Shanghai, China). An unrelated sequence was used as a negative
control (provided by GenPharm).
X. Chen et al. / FEBS Letters 587 (2013) 3729–3737 37312.10. Cell cycle assay
Transfected SH-SY5Y or GI-Li-N cells were seeded into 6-well
plates for 24 h in complete medium before cells were deprived of
serum for 48 h and then returned to complete medium for an addi-
tional 24 h. All cells were collected by centrifugation, ﬁxed in 95%
ethanol, incubated at 20 C overnight and washed with phos-
phate buffered saline (PBS). Then, cells were resuspended in 1 ml
FACS solution (PBS, 0.1% TritonX-100, 60 ug/ml propidium iodide
(PI), 0.1 mg/ml DNase free RNase, and 0.1% trisodium citrate). After
a ﬁnal incubation on ice for 30 min, cells were analyzed using a
FACS Calibur ﬂow cytometer (Beckman Coulter). A total of 10000
events were counted for each sample.
2.11. Quantiﬁcation of PI(4,5)P2 for determination activity of PTEN
For PI(4,5)P2 quantiﬁcation, SH-SY5Y and GI-Li-N cells were
plated in 6-well plates and transfected in three parallels with
PREX2a siRNA and control for 48 h. PI(4,5)P2 was quantiﬁed using
the PI(4,5)P2 Mass ELISA kit (Echelon Biosciences, Salt Lake City,
UT, USA) following the manufacturer’s instructions. Brieﬂy, cells
were incubated with cold 0.5 M TCA for 5 min, centrifuged and
resuspended in 5% TCA/1 mM EDTA. After centrifugation, neutral
lipids were extracted with methanol:chloroform (2:1) and acidic
lipids with methanol:chloroform:12 M HCl (80:40:1). The extracts
were centrifuged and chloroform plus 0.1 M HCl were added to the
supernatant followed by centrifugation to separate organic and
aqueous phases. The organic phase was dried in a vacuum dryer.
Then, extracted lipids were resuspended in PBS 0.25% protein sta-
bilizer, incubated with a PI(4,5)P2 detector protein for 1 h at room
temperature and then added to a 96-well PI(4,5)P2-coated micro-
plate. A peroxidase-linked secondary detection reagent and a
colorimetric substrate were added to detect the PI(4,5)P2 detector
protein binding to the plate. The colorimetric signals were
measured at 450 nm using a Tecan M1000 instrument. The data
represent PI(4,5)P2 levels in pmol/mg cell lysate calculated from
the standard curve generated according to the manufacturer’s
instructions.
2.12. Statistical analysis
A Student’s test was performed to analyze the signiﬁcance of
differences between the sample means obtained from three
independent experiments. Differences were considered statisti-
cally signiﬁcant at P < 0.05.Fig. 1. Identiﬁcation of the differential expression of miR-338-3p in neuroblastoma tissu
site and primary site were detected by quantitative RT-PCR. GAPDH was used as endogen
neuroblastoma tissues as well as the combined result (mean ± S.D.) is shown. ⁄p < 0.05.3. Results
3.1. Down-regulation of miR-338-3p in metastatic NB compared to
primary NB
Previously, we established a heterotopic transplant mice model
of NB and performed a microarray-based analysis identifying
expression of miR-338-3p was decreased (a 34% reduction) in six
metastatic tumor tissues compared with paired primary tumor
tissues [2]. To investigate the potential involvement of the miR-
338-3p in the process of human NB metastasis, we measured the
expression levels of miR-338-3p in eighteen pairs of human tis-
sues. As shown in Fig. 1, we found that miR-338-3p expression lev-
els had an average of 36% reduction in metastatic tumor tissues
compared with paired primary tumor tissues, which was consis-
tent with the results of animal models.
3.2. miR-338-3p suppresses NB cell growth in vitro
Although the anti-oncogenic contribution of miR-338-3p has
been described in liver cancer [12] and colorectal carcinoma [13],
the biological signiﬁcance of miR-338-3p in NB has not been inves-
tigated in detail. Gain/loss-of-function experiments are widely
used for functional studies of miRNAs. To investigate the role of
miR-338-3p in NB cell growth, miR-338-3p mimics and antisense
oligonucleotide (ASO) were synthesized, and the transfection efﬁ-
ciency was conﬁrmed by qRT-PCR, which indicated a 12/15-fold in-
crease and 70/65% reduction in SH-SY5Y and GI-Li-N cells (Fig. 2A).
To characterize the effects of miR-338-3p on cell growth, cells were
transfected with miR-338-3p mimics or ASO, and growth was
monitored using growth curve (Fig. 2B, C) and colony formation as-
says (Fig. 2D), which indicated that overexpression of miR-338-3p
inhibited SH-SY5Y and GI-Li-N cells growth, while miR-338-3p
ASO exhibited opposite effect, indicating that miR-338-3p sup-
pressed NB cell viability and its long-term proliferative capacity.
To follow up the ﬁnding that miR-338-3p could decrease
growth of NB cells, FACS was used to analyze whether miR338-
3p can affect cell cycle. As shown in Fig. 2E, overexpression of
miR-338-3p resulted in a signiﬁcant increase of cells in G1 phase
(from 55% to 79% in SH-SY5Y cells and from 61% to 84% in GI-Li-
N cells), an obvious decrease of cells in S phase (from 37% to 16%
in SH-SY5Y cells and from 28% to 17% in GI-Li-N cells), compared
to the control. The results demonstrated that miR-338-3p can
serve as a tumor suppressor in neuroblastoma.es. The expression level of miR-338-3p in eighteen pairs of tissues from metastasis
ous normalizer. The relative expression level of miR-338-3p in the eighteen pairs of
Fig. 2. The effect of miR-338-3p on SH-SY5Y and GI-Li-N cell proliferation. (A) SH-SY5Y and GI-Li-N cells were transfected with miR-338-3p mimics or ASO. The expression
level of miR-338-3p was detected by qRT-PCR. (B and C) Cell growth curve assay was performed to investigate the effect of miR-338-3p on the proliferation of SH-SY5Y and
GI-Li-N cells at indicated time points. (D) Colony formation assay of SH-SY5Y and GI-Li-N cells. (E) The effect of miR-338-3p on cell cycle progression. The indicated
percentages are the average of three independent experiments, ⁄p < 0.05.
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NB has an unexplained metastasis tendency to bone marrow, li-
ver and non-contiguous lymph nodes [14]. Children with bone
metastasis have a mortality rate greater than 90% [15]. Thus,
understanding the nature of metastatic NB is of great importance.
Our result showed that metastatic tumor tissues had signiﬁcant
decrease of miR-338-3p, implying its potential role in regulating
the NB metastasis. Therefore, we conducted invasion and migra-
tion assays. Transwell assay demonstrated that overexpression of
miR-338-3p reduced the invasion of SH-SY5Y cells by 47% and
GI-Li-N cells by 40% when compared to the control cells. In con-
trast, miR-338-3p ASO increased the invasion of SH-SY5Y cells by
2.1-fold and GI-Li-N cells by 1.4-fold (Fig. 3A) when compared with
ASO-NC. Wounding healing assays further conﬁrmed that miR-
338-3p suppressed NB cell migration (Fig. 3B).Fig. 3. Inﬂuences of miR-338-3p on migration and invasion ability in neuroblastoma cells
338-3p mimics or ASO were determined by transwell assay (A) and wound healing assa
Table 1
mRNA expression proﬁle detected by cDNA chip when miR-338-3p was transfected.
Gene symbol Gene name Accession n
UBE2Q Ubiquitin-conjugating enzyme E2Q family member 1 NM_01758
ZNF470 Zinc ﬁnger protein 470 NM_00100
PREX2 Phosphatidylinositol-3,4,5-trisphosphate-dependent
Rac exchange factor 2
NM_02487
STXBP1 Syntaxin binding protein 1 NM_00316
CCND1a Cyclin D1 NM_05305
NR3C2 Nuclear receptor subfamily 3, group C, member 2 NM_00090
SENP2 SUMO1/sentrin/SMT3 speciﬁc peptidase 2 NM_02162
EPAS1 Endothelial PAS domain protein 1 NM_00143
KIAA1456 Putative methyltransferase KIAA1456 NM_00109
a It has been identiﬁed as miR-338-3p target by Fu X et al. [22].3.4. PREX2a serves as a target of miR-338-3p for post-transcriptional
repression
To investigate the mechanisms through which miR-338-3p in-
duces growth arrest and represses invasion, we examined pre-
dicted overlapping target sets using four algorithms: Target-Scan
Human 5.1, PicTar, mirna.org, and mirdb by microarray assay. Sev-
eral interesting genes were predicted to be targets of miR-338-3p,
many of which are involved in neural or cancer-associated pro-
cesses (Table 1). One gene in particular, PREX2a, scored well in
all algorithms used and was selected for further analysis. Inspec-
tion of the 30-UTR of PREX2a revealed three potential miR-338-
3p target sites that was closely positioned (Fig. 4A). To demon-
strate that miR-338-3p directly regulates PREX2a expression, we
transfected a PREX2a 30-UTR luciferase reporter construct together
with miR-338-3p mimics or ASO into SH-SY5Y cells and noticed an. The changes of cell migration and invasion ability affected by transfected with miR-
y; (B) ⁄p < 0.05.
umber SH-SY5Y IMR-32 Target Scan Microrna Pictar Mirdb
2 0.58 0.36  + + 
1668 0.64 0.71  +  +
0 0.32 0.44 + +  +
5 0.71 0.47   + 
6 0.63 0.72 + + + 
1 0.29 0.74   + 
7 0.61 0.78  +  +
0 0.65 0.49    +
9677 0.39 0.68 +   +
Table 2
The oligonucleotides used in this work.
miR-338-3p
RT primer GTCGTATCCAGTGCAGGGTCCGAGGTGCACTGGATACGACCAACAAAA
Forward TGCGGTCCAGCATCAGTGAT
Reverse CCAGTGCAGGGTCCGAGGT
U6
RT primer GTCGTATCCAGTGCAGGGTCCGAGGTGCACTGGATACGACAAAATATGG
U6 Forward TGCGGGTGCTCGCTTCGGCAGC
U6 reverse CCAGTGCAGGGTCCGAGGT
3734 X. Chen et al. / FEBS Letters 587 (2013) 3729–373760% reduction and 1.8-fold increase in luciferase activity compared
to cells transfected with the control. Conversely, no reduction or
increase in luciferase activity was detected with the miR-338-3p
seed-mutant PREX2a 30-UTR reporter construct (Fig. 4B), demon-
strating that the introduced target site mutations abolished the
ability of miR-338-3p to regulate the PREX2a 30-UTR in these set-
tings. Taken together, these data suggests that PREX2a expression
may be negatively regulated via miR-338-3p 30-UTR miRNA bind-
ing sites. To assess miR-338-3p-mediated repression of endoge-
nous PREX2a, we overexpressed miR-338-3p using mimics in
both SH-SY5Y and GI-Li-N cells. Ectopic expression of miR-338-
3p resulted in a substantial down-regulation (70% in SH-SY5Y
and 65% in GI-Li-N cells) of PREX2a protein levels, while miR-
338-3p ASO lead to an increase of the PREX2 protein levels (2.4-
fold and 1.7-fold, seperatively), we also conﬁrmed the results in
another cell line IMR-32 (40% decrease and 2.1-fold increase)
(Fig. 4C), indicating that miR-338-3p can directly down-regulate
the PREX2a expression.Fig. 4. miR-338-3p directly targets PREX2a and inhibits its expression. (A) A schematic of
30UTR used in this study is shown above. (B) Effect of miR-338-3p on the luciferase activit
transfected with miR-338-3p mimics or ASO and PREX2a-3UTR or 3UTR-mut, then harve
PREX2a protein.3.5. Knockdown of PREX2a represses proliferation, migration and
invasion of NB cells
It has been demonstrated that PREX2a can decrease PTEN lipid
phosphatase activity, as a consequence, leading to an increase
activity of the kinase AKT to promote cellular growth, thereby con-
tributing to oncogenesis. However, the mechanism has not been
identiﬁed in neuroblastoma cells. Therefore, speciﬁc siRNA target-
ing PREX2a was transfected into SH-SY5Y and GI-Li-N cells and
Western blotting showed PREX2a siRNA caused a signiﬁcant reduc-
tion of PREX2a protein levels in SH-SY5Y and GI-Li-N cells (Fig. 5A).
Cells with reduced levels of PREX2a had a signiﬁcant increase of
PTEN activity and decrease on the phosphorylation of AKT
(Fig. 5A and B), indicating PREX2a can affect NB cells function
through PREX2a/PTEN/AKT pathway. In order to further shed light
on the function of PREX2a in vitro, we undertook colony formation,
cell invasion and wound healing assays. Cells with reduced levels
of PREX2a had a decreased rate in colony formation rate compared
to the negative control cells (Fig. 5C). Furthermore, cells expressing
reduced PREX2a signiﬁcantly decreased invasion ability of tumor
cells through Matrigel (Fig. 5D) and the rate of migration of cells
into a denuded area of conﬂuent monolayer (Fig. 5E). All these
ﬁndings showed that knockdown of PREX2a inhibited NB cell
growth, migration and invasion.
3.6. Role of miR-338-3p in PREX2a-mediated NB cell growth
We have demonstrated that miR-338-3p can directly and nega-
tively regulate PREX2a expression, therefore, we aimed to explore
whether miR-338-3p repressed NB cell growth, invasion wasthe bioinformatics predicted seed region in the 30UTR of PREX2a as well as mutated
y of PREX2a-30UTR and PREX2a-30UTR-mut. For 3UTR reporter assays, cells were co-
sted for lysis of cells 48 h after transfection. (C) Western blot was used to detect the
Fig. 5. Knockdown of PREX2a on NB cells proliferation, invasion and migration. (A) Western blot was used to detect the effect of PREX2a siRNA plasmid on PREX2a protein
level. (B) The activity of PTEN was evaluated by ELISA. Knockdown the expression of PREX2a suppressed the proliferation; (C) invasion; (D) and migration; (E) of indicated
cells.
X. Chen et al. / FEBS Letters 587 (2013) 3729–3737 3735
3736 X. Chen et al. / FEBS Letters 587 (2013) 3729–3737mediated by PREX2a. We co-transfected miR-338-3p ASO and PRE-
X2a siRNA into SH-SY5Y and GI-Li-N cells and evaluated whether
the effects caused by blocking miR-338-3p can be aborted by the
knockdown of PREX2a. As shown in Fig. 6A, the induction of PRE-
X2a expression caused by miR-338-3p ASO can be partly rescued
by the reduction of PREX2a by transfection of PREX2a siRNA. The
colony formation assay indicated that inhibition of PREX2a abro-
gated miR-338-3p ASOmediated SH-SY5Y and GI-Li-N cells growth
(Fig. 6B). We further examined the cell metastasis alteration in this
process and found that transfection of SH-SY5Y and GI-Li-N cells
with PREX2a siRNA, but not siRNA NC, ablated the miR-338-3p
ASO induced cell invasion (Fig. 6C). These results suggested that
miR-338-3p-repressed NB cell growth, invasion was mediated by
down-regulation of PREX2a.
4. Discussion
Over the past decades, researchers have indentiﬁed numerous
genes contribute to NB growth, invasion and migration. The dys-
regulated expression of miRNAs have been found to correlate with
these phenotypes, thus reinforcing the importance of miRNA biol-
ogy in NB-associated tumorigenesis. Researchers found miR-34a
induced cell cycle arrest and subsequent apoptosis activation in
NB cells [16]. The overexpression of miR-128 in SH-SY5Y cells
can increase cell number, proliferation, with a remarkable upregu-
lation of Bcl2, an important anti-apoptosis protein that inhibits
caspase activity [17]. Metastasis is a major cause of NB-related
death and patients with NB have a tendency to develop malignant
lesions outside the primary tumor. It has been identiﬁed that miR-
29-a/b was overexpressed in metastatic neuroblastoma and two of
this miRNAs predicted targets were CASP8 and integrins, the ab-
sence of which have been implicated in neuroblastoma metastasis
in vivo [18]. Other related miRNAs associated with NB metastasis
include mir-10b, miR-335 and let-7 miRNA family [19,20], etc.
Published data have indicated that the proliferative potential of
colorectal carcinoma cells was suppressed after miR-338-3p over-
expression, due to miR-338-3p suppressed cell cycle at G0/G1
phase and induced apoptosis [21]. In this study, we identiﬁed
miR-338-3p could suppress NB cells (SH-SY5Y and GI-Li-N)
growth, invasion and migration using cell growth curve, colonyFig. 6. MiR-338-3p induced NB cell growth and invasion was mediated by PREX2a.
cotransfected with miR-338-3p ASO and siRNA NC, or miR-338-3p ASO and PREX2a siRN
assay was used to detected cell proliferation activity; (B) Transwell assay was used to dformation, FACS, as well as transwell and wound healing assays,
further demonstrating the tumor suppressor role of miR-338-3p.
To date, the mechanism of miR-338-3p function in neuroblas-
toma has not been investigated, although several targets have been
identiﬁed including CyclinD1, Runx2, smoothened with a key role
affecting cell cycle, differentiation and invasion [12,22,23]. Here,
We identiﬁed PREX2a as a novel target of miR-338-3p. PREX2a
can directly interact with PTEN to inactivate its lipid phosphatase
activity, leading to accumulation of PIP3 and as a consequence
increasing phosphorylation of threonine-308 AKT and serine-473
AKT, which promotes cellular survival, cell cycle progression, and
growth, thereby contributing to oncogenesis. To test whether
endogenous PREX2a inﬂuenced the PI3K pathway in NB cells, we
transfected SH-SY5Y and GI-Li-N cells with PREX2a siRNA and dis-
played increased activity of PTEN and decreased amounts of pAKT.
It also reduced cell proliferation, invasion and migration after
introduction of PREX2a siRNAs.
As previously indicated miR-338-3p is transcribed from the in-
tron 8 of apoptosis-associated tyrosine kinase (AATK) gene, located
on chromosome 17q25, playing a critical role in promoting cell
death, neuronal differentiation and neurite extension [24,25]. A
point that deserves further investigation is the potential contribu-
tion of miR-338-p host gene ATKK in the regulation of neuroblas-
toma. Cécile Jacovetti [26] found that during gestation in rat
islets under insulin resistance conditions, the decrease in AATK lev-
els parallels that of miR-338-3p, indicating a cooperative action of
miR-338-3p and its hosting gene. Since Cdk5 activator p35 was
found to bind and phosphorylate AATK [27], and Cdk5 has been
identiﬁed exerting a key role in promoting neuronal survival by
regulating Akt activity through neuregulin/PI3K signalling path-
way [28], therefore we speculate that ATKK may function through
Cdk5/ATKK/Akt pathway to cooperate with miR-338-3p exerting
its regulation effect in neuroblastoma. However, the potential
mechanism needs to be further investigated.
In conclusion, this present study ﬁrst identiﬁed PREX2a was di-
rectly and negatively regulated by miR-338-3p, which was down-
regulated in NB metastasis tumor tissues and function as tumor
suppressor, as we found miR-338-3p can inhibit SH-SY5Y and GI-
Li-N cells proliferation, migration and invasion. Further we identi-
ﬁed that PREX2a exerted its function through PTEN/Akt pathway,SH-SY5Y and GI-Li-N cells were transfected with ASO-NC, miR-338-3p ASO, or
A. PREX2a protein level was detectd by western blot analysis; (A) Colony formation
etected the cells invasion ability; (C) ⁄p < 0.05.
X. Chen et al. / FEBS Letters 587 (2013) 3729–3737 3737therefore miR-338-3p may regulate PTEN/Akt pathway by sup-
pressing PREX2a expression. These ﬁndings may have potentially
relevant therapeutic implications in NB diagnosis.
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